Rosauro Varo
Rosauro Varo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Quique Bassat
Affiliations Centro de Investigação em Saúde de Manhiça [CISM], Maputo, Mozambique, ISGlobal - Hospital Clínic, Universitat de Barcelona, Barcelona, Spain, Institutó Catalana de Recerca i Estudis Avançats [ICREA], Barcelona, Spain, Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain, CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
3 shared publications - Lola Madrid
Affiliations Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine, London, United Kingdom, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
2 shared publications Ana Marta Valente
Ctr Invest Saude Manhica, Maputo, Mozambique
1 shared publicationAntonio Sitoe
Centro de Investigação em Saúde de Manhiça, Rua 12, Vila da Manhiça, 1929, Maputo, Mozambique
1 shared publication- Antonio Sitoe
Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
1 shared publication Dianna M. Blau
Ctr Dis Control & Prevent, Atlanta, GA USA
1 shared publication
Latest Publications
- Open Access
- 1 August 2019
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 25 (8) , 1614-1616
Sneathia amniiand Maternal Chorioamnionitis and Stillbirth, Mozambique
We report a case of Sneathia amnii as the causative agent of maternal chorioamnionitis and congenital pneumonia resulting in a late fetal death in Mozambique, with strong supportive postmortem molecular and histopathological confirmation. This rare, fastidious gram-negative coccobacillus has been reported to infrequently cause abortions, stillbirths, and neonatal infections.
- 1 August 2019
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 25 (8) , 1614-1616
Open AccessSneathia amniiand Maternal Chorioamnionitis and Stillbirth, Mozambique
We report a case of Sneathia amnii as the causative agent of maternal chorioamnionitis and congenital pneumonia resulting in a late fetal death in Mozambique, with strong supportive postmortem molecular and histopathological confirmation. This rare, fastidious gram-negative coccobacillus has been reported to infrequently cause abortions, stillbirths, and neonatal infections.
- Open Access
- 25 April 2018
- Published by MDPI AG in Biosensors
- Vol. 8 (2) , 43
Continuous Glucose Monitoring in Resource-Constrained Settings for Hypoglycaemia Detection: Looking at the Problem from the Other Side of the Coin
The appearance, over a decade ago, of continuous glucose monitoring (CGM) devices has triggered a patient-centred revolution in the control and management of diabetes mellitus and other metabolic conditions, improving the patient’s glycaemic control and quality of life. Such devices, the use of which remains typically restricted to high-income countries on account of their elevated costs, at present show very limited implantation in resource-constrained settings, where many other urgent health priorities beyond diabetes prevention and management still need to be resolved. In this commentary, we argue that such devices could have an additional utility in low-income settings, whereby they could be selectively used among severely ill children admitted to hospital for closer monitoring of paediatric hypoglycaemia, a life-threatening condition often complicating severe cases of malaria, malnutrition, and other common paediatric conditions.
- 25 April 2018
- Published by MDPI AG in Biosensors
- Vol. 8 (2) , 43
Open AccessContinuous Glucose Monitoring in Resource-Constrained Settings for Hypoglycaemia Detection: Looking at the Problem from the Other Side of the Coin
The appearance, over a decade ago, of continuous glucose monitoring (CGM) devices has triggered a patient-centred revolution in the control and management of diabetes mellitus and other metabolic conditions, improving the patient’s glycaemic control and quality of life. Such devices, the use of which remains typically restricted to high-income countries on account of their elevated costs, at present show very limited implantation in resource-constrained settings, where many other urgent health priorities beyond diabetes prevention and management still need to be resolved. In this commentary, we argue that such devices could have an additional utility in low-income settings, whereby they could be selectively used among severely ill children admitted to hospital for closer monitoring of paediatric hypoglycaemia, a life-threatening condition often complicating severe cases of malaria, malnutrition, and other common paediatric conditions.
- Open Access
- 24 January 2018
- Published by Springer Nature in Malaria Journal
- Vol. 17 (1) , 1-18
Adjunctive therapy for severe malaria: a review and critical appraisal
Despite recent efforts and successes in reducing the malaria burden globally, this infection still accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,000 deaths annually. Even with the routine use of effective anti-malarial drugs, the case fatality rate for severe malaria remains unacceptably high, with cerebral malaria being one of the most life-threatening complications. Up to one-third of cerebral malaria survivors are left with long-term cognitive and neurological deficits. From a population point of view, the decrease of malaria transmission may jeopardize the development of naturally acquired immunity against the infection, leading to fewer total cases, but potentially an increase in severe cases. The pathophysiology of severe and cerebral malaria is not completely understood, but both parasite and host determinants contribute to its onset and outcomes. Adjunctive therapy, based on modulating the host response to infection, could help to improve the outcomes achieved with specific anti-malarial therapy. In the last decades, several interventions targeting different pathways have been tested. However, none of these strategies have demonstrated clear beneficial effects, and some have shown deleterious outcomes. This review aims to summarize evidence from clinical trials testing different adjunctive therapy for severe and cerebral malaria in humans. It also highlights some preclinical studies which have evaluated novel strategies and other candidate therapeutics that may be evaluated in future clinical trials.
- 24 January 2018
- Published by Springer Nature in Malaria Journal
- Vol. 17 (1) , 1-18
Open AccessAdjunctive therapy for severe malaria: a review and critical appraisal
Despite recent efforts and successes in reducing the malaria burden globally, this infection still accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,000 deaths annually. Even with the routine use of effective anti-malarial drugs, the case fatality rate for severe malaria remains unacceptably high, with cerebral malaria being one of the most life-threatening complications. Up to one-third of cerebral malaria survivors are left with long-term cognitive and neurological deficits. From a population point of view, the decrease of malaria transmission may jeopardize the development of naturally acquired immunity against the infection, leading to fewer total cases, but potentially an increase in severe cases. The pathophysiology of severe and cerebral malaria is not completely understood, but both parasite and host determinants contribute to its onset and outcomes. Adjunctive therapy, based on modulating the host response to infection, could help to improve the outcomes achieved with specific anti-malarial therapy. In the last decades, several interventions targeting different pathways have been tested. However, none of these strategies have demonstrated clear beneficial effects, and some have shown deleterious outcomes. This review aims to summarize evidence from clinical trials testing different adjunctive therapy for severe and cerebral malaria in humans. It also highlights some preclinical studies which have evaluated novel strategies and other candidate therapeutics that may be evaluated in future clinical trials.